Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Ruth NabisereJoseph MusaaziPaolo DentiFlorence AberMohammed LamordeKelly E DooleyRob AarnoutseDerek J SloanChristine Wiltshire SekaggyaPublished in: Trials (2020)
ClinicalTrials.gov, ID: NCT03982277. Registered retrospectively on 11 June 2019.
Keyphrases
- antiretroviral therapy
- phase ii
- open label
- high dose
- clinical trial
- hiv aids
- mycobacterium tuberculosis
- hiv infected
- hiv infected patients
- hiv positive
- human immunodeficiency virus
- pulmonary tuberculosis
- double blind
- placebo controlled
- phase iii
- low dose
- stem cell transplantation
- study protocol
- drug induced
- men who have sex with men
- hiv testing